Filtered By:
Specialty: Cardiology
Drug: Zetia
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 100 results found since Jan 2013.
Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial.
CONCLUSIONS: LDL-C-lowering therapy with ezetimibe prevented cardiovascular events, suggesting the importance of LDL-C lowering for primary prevention in individuals aged ≥75 years with elevated LDL-C. Given the open label nature of the trial, its premature termination and issues with follow up, the magnitude of benefit observed should be interpreted with caution.
CLINICAL TRIAL REGISTRATION: URL: https://www.umin.ac.jp Unique identifier: UMIN000001988.
PMID: 31434507 [PubMed - as supplied by publisher]
Source: Circulation - August 21, 2019 Category: Cardiology Authors: Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, Urabe T, Uchida Y, Hayashi M, Yokota N, Nishida H, Otonari T, Arai T, Sakuma I, Sakabe K, Yamamoto M, Kobayashi T, Oikawa S, Yamashita S, Rakugi H, Imai T, Tanaka S, Ohashi Y, Kuwabara M, Ito H Tags: Circulation Source Type: research
Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention - A Meta-Analysis of 12 Randomized Trials.
CONCLUSIONS: In secondary prevention patients, the relative benefits of high-dose statin, ezetimibe-statin, and PCSK9 inhibitor-statin treatments were varied and decreased gradually, of which high-dose statin was significantly superior to PCSK9 inhibitor-statin for improving MACE and revascularization per 1 mmol/L reduction of LDL-C.
PMID: 31006730 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 18, 2019 Category: Cardiology Authors: Wang S, Xiu J, Liao W, Liao Y, Bin J Tags: Circ J Source Type: research
Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain
ConclusionsTreatment with evolocumab is associated with a lower frequency of cardiovascular events, but is inefficient for patients suitable to receive this drug in the Spanish National Health System.ResumenIntroducción y objetivosAnalizar la razón de coste-efectividad y el impacto presupuestario del tratamiento con evolocumab (inhibidor de la PCSK9) para pacientes en prevención secundaria en el Sistema Nacional de Salud español.MétodosSe realizaron, desde la perspectiva del sistema sanitario público, análisis de impacto presupuestario, modelos de árbol de decisión y Markov, basándose en el único ensayo clínico...
Source: Revista Espanola de Cardiologia - July 10, 2018 Category: Cardiology Source Type: research
Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891625 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Bohula EA, Wiviott SD, Giugliano RP, Park JG, Murphy SA, Cannon CP, Braunwald E Tags: Circulation Source Type: research
Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891624 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Koh KK Tags: Circulation Source Type: research
Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891623 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Cordero A, Bertomeu-González V, Rodriguez-Mañero M Tags: Circulation Source Type: research
Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891622 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Thomopoulos C, Michalopoulou H Tags: Circulation Source Type: research
Letter by Del Pinto et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891621 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Del Pinto R, Ferri C, Borghi C Tags: Circulation Source Type: research
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT.
Conclusions -In IMPROVE-IT the benefit of adding ezetimibe to statin was enhanced in patients with DM and in high-risk non-diabetics. Clinical Trial Registration -URL: https://clinicaltrials.gov Unique Identifier: NCT00202878.
PMID: 29263150 [PubMed - as supplied by publisher]
Source: Circulation - December 20, 2017 Category: Cardiology Authors: Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park JG, White JA, Bohula E, Braunwald E, IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators Tags: Circulation Source Type: research
The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender.
CONCLUSIONS: The results of our study demonstrated that when added to statin therapy, EZE resulted in improved cardiovascular outcomes, and the response to atorvastatin and EZE combination was similar for both men and women.
PMID: 28553847 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - December 6, 2017 Category: Cardiology Authors: Japaridze L, Sadunishvili M Tags: Kardiol Pol Source Type: research
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
ConclusionReduction of MVE is proportional to the magnitude of LDL-C lowering across a broad spectrum of on-treatment levels in secondary prevention. Statin intensification and add-on treatment with PCSK9 inhibitors or ezetimibe are associated with significant reduction of cardiovascular morbidity in this very high-risk population.
Source: European Heart Journal - October 23, 2017 Category: Cardiology Source Type: research
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT.
Conclusions -The addition of ezetimibe to simvastatin in patients stabilized after ACS reduces the frequency of ischemic stroke, with a particularly large effect seen in patients with a prior stroke. Clinical Trial Registration -URL: http://www.clinicaltrials.gov Unique Identifier: NCT00202878.
PMID: 28972004 [PubMed - as supplied by publisher]
Source: Circulation - September 30, 2017 Category: Cardiology Authors: Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf FJ, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E Tags: Circulation Source Type: research
Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.
CONCLUSIONS: Main manifestations of ASCVD in FH patients were premature, multivessel CAD with need for recurrent revascularization, associated with classical cardiovascular risk factors but not with peak LDL-C. In spite of intensive therapy with lipid-lowering agents, treatment gaps were significant, with low attainment of LDL-C treatment goals.
PMID: 28701632 [PubMed - as supplied by publisher]
Source: Circulation Journal - July 12, 2017 Category: Cardiology Authors: Zafrir B, Jubran A, Lavie G, Halon DA, Flugelman MY, Shapira C Tags: Circ J Source Type: research
